W Scheithauer
Overview
Explore the profile of W Scheithauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
4678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andre T, Vernerey D, Im S, Bodoky G, Buzzoni R, Reingold S, et al.
Ann Oncol
. 2020 Jan;
31(2):246-256.
PMID: 31959341
Background: The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point of improving disease-free survival (DFS) with the addition of bevacizumab to oxaliplatin-based chemotherapy in stage III colon...
2.
Holch J, Held S, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Ann Oncol
. 2020 Jan;
31(1):72-78.
PMID: 31912799
Background: Cetuximab-induced skin toxicity (Cet-ST) is positively associated with outcome in metastatic colorectal cancer (mCRC). Besides its predictive relevance for targeted therapy, we investigated its prognostic impact with early tumor...
3.
Stintzing S, Wirapati P, Lenz H, Neureiter D, Fischer von Weikersthal L, Decker T, et al.
Ann Oncol
. 2019 Dec;
30(11):1796-1803.
PMID: 31868905
Background: FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping...
4.
Holch J, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Eur J Cancer
. 2018 Nov;
106:115-125.
PMID: 30496943
Purpose: Increased baseline carcinoembryonic antigen (CEA) serum level is associated with inferior overall survival (OS) in metastatic colorectal cancer (mCRC). However, limited data exist on its predictive relevance for targeted...
5.
Unseld M, Filip M, Seirl S, Gleiss A, Bianconi D, Kieler M, et al.
Neoplasma
. 2018 Jun;
65(4):599-603.
PMID: 29940763
The oral multikinase inhibitor regorafenib had beneficial effects in randomized clinical phase III trials compared to the placebo in patients with metastatic colorectal cancer (mCRC) who progressed on standard therapies....
6.
Modest D, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Eur J Cancer
. 2017 Aug;
84:262-269.
PMID: 28843184
Background: We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in FIRE-3 were investigated in the context of...
7.
Stintzing S, Miller-Phillips L, Modest D, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Eur J Cancer
. 2017 May;
79:50-60.
PMID: 28463756
Background: RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab in patients with RAS-mutant tumours needs...
8.
Van Cutsem E, Cervantes A, Adam R, Sobrero A, van Krieken J, Aderka D, et al.
Ann Oncol
. 2016 Jul;
27(8):1386-422.
PMID: 27380959
Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with...
9.
Michl M, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, et al.
Ann Oncol
. 2016 May;
27(8):1565-72.
PMID: 27234640
Background: To examine the relation of carcinoembryonic antigen (CEA) response with tumor response and survival in patients with (K)RAS wild-type metastatic colorectal cancer receiving first-line chemotherapy in the FIRE-3 trial...
10.
Scheithauer W, Van Cutsem E
Colorectal Dis
. 2013 Apr;
5 Suppl 3:36-44.
PMID: 23573559
Following the successful introduction of oxaliplatin into the management of advanced colorectal cancer, its clinical utility is currently being investigated in a variety of other malignancies, including cancers of the...